Waystar Holding Corp. (WAY) Stock Analysis and Metrics

Waystar Holding

NASDAQ: WAY

$22.51 ▲ +0.93 (+4.31%)

At close: Jul 24, 2026 · 4:00 PM UTC

Financial Ratios

Market Cap4.14 Bn

P/E32.80

P/S3.58

Div. Yield0.00

ROIC (Qtr)0.05

Total Debt (Qtr)1.47 Bn

Revenue Growth (1y) (Qtr)22.40

Add ratio to table…

About

Waystar Holding Corp. provides healthcare organizations with mission critical AI powered software that simplifies healthcare payments. Our enterprise grade platform streamlines the complex and disparate processes providers must manage to ensure accurate reimbursement and improves the payments experience for providers patients and payers. We leverage internally developed AI and proprietary advanced algorithms to automate payment related workflow tasks and drive continuous improvement which enhances claim and billing accuracy strengthens data integrity and reduces labor costs for providers. Put simply our software helps providers get paid faster accurately and more efficiently while ensuring patients receive a modern transparent and consumer friendly financial experience. The software supports pre encounter activities such as eligibility checks and prior authorizations as well as mid encounter functions like utilization management coding accuracy and documentation improvement. On the back end it assists with claims submission payment posting denial management and patient payment collection through a unified portal. By processing billions of transactions each year the platform accumulates data that feeds its AI models and creates a self reinforcing cycle of improvement. This network effect allows the system to adapt to evolving payer rules and regulatory changes delivering ongoing value to clients.

Waystar Holding Corp. generates revenue primarily through subscription fees and volume based charges tied to the use of its software platform. Contracts with clients typically include a fixed recurring subscription fee plus a variable component that grows with patient volumes claims and transactional activity. The company also benefits from additional sales of supplementary services and from upselling and cross selling to existing customers as they adopt more solutions or expand to new sites of care. Over 99% of revenue is either recurring subscription or based on highly predictable volumes providing visibility into future earnings. High retention is demonstrated by a net revenue retention rate of 112% for the year ended December 31 2025 indicating that existing customers increase their spending over time. The business model benefits from the fact that as clients serve more patients and process more claims the usage of the platform rises driving corresponding revenue growth. This alignment with client growth creates a scalable revenue stream that is less dependent on acquiring new logos alone.

Waystar Holding Corp. operates in a highly fragmented and competitive market for healthcare payment software where it faces competition from revenue cycle technology vendors point solution vendors EHR and PM systems providers and providers internal systems. The company believes its competitive advantages stem from the breadth depth and quality of its solutions its innovative AI powered platform its deep domain expertise developed over two decades the differentiated client service it provides and the return on investment it delivers. Additional strengths include leading edge technology and innovation the ability to integrate with various EHR and PM systems ease of use and convenience and strong brand recognition. The firm’s long history in the sector has produced a deep library of rules algorithms and payer contracts that are difficult for newcomers to replicate. This expertise allows the platform to deliver accurate predictions and recommendations that reduce denials and improve first pass claim acceptance rates. Furthermore the organization’s focus on customer success and high touch support contributes to strong loyalty and referrals among providers.

Waystar Holding Corp. serves over 30,000 healthcare client organizations ranging from physician practices clinics surgical centers laboratories and large hospitals and health systems. The client base includes 16 of the top 20 U. S. News Best Hospitals and represents over 1,000,000 individual providers across various care settings. For the year ended December 31 2025 the top 10 clients accounted for only 10.8% of total revenue showing a diversified revenue base. The company reports that the number of clients generating more than $100,000 in annual revenue increased from 1,203 in 2024 to 1,391 in 2025. This growth reflects successful upselling cross selling and the addition of new logos especially among larger health systems and ambulatory providers. Despite the lack of long term contractual obligations the high retention rates suggest that clients find the platform indispensable for their revenue cycle operations.

Investment Thesis

▲ Bull case

Waystar is positioned to capture significant value from the healthcare revenue cycle labor services market, which represents approximately $100 billion annually, by extending its AI-powered platform beyond the traditional $20 billion software TAM. Management emphasized that embedding Agentic AI into mission-critical workflows allows the company to automate high-volume, repetitive tasks such as denials, prior authorizations, and recoupments, areas where payers are increasingly offsetting previously paid claims with little transparency. This shift is not merely incremental but transformative, as it enables Waystar to monetize outcomes directly tied to labor cost avoidance rather than just software subscriptions. The company’s early traction with its new recruitment solution — reducing reconciliation time by over 80% and enabling one health system to identify $32 million in recoverable revenue — demonstrates a clear path to monetizing this vast addressable market. Furthermore, Waystar’s proprietary data advantage, derived from processing over 7.5 billion transactions annually and clinical insights from one-third of U.S. hospital discharges, creates a formidable moat that competitors cannot easily replicate, especially given the industry’s intolerance for AI hallucinations in regulated environments. This structural shift from selling software to selling autonomous financial outcomes positions Waystar to sustain growth well above its current 10% normalized organic guidance, with AI-driven bookings already constituting 40% of new wins in Q1 and accelerating cross-sell momentum from the Iodine integration, which bridges the critical mid-cycle gap between clinical and financial data.
Waystar’s capital allocation strategy, including the newly authorized $200 million stock repurchase plan, signals strong internal confidence in intrinsic value creation and provides a tangible floor to downside risk while enhancing long-term per-share returns. The repurchase authorization, coupled with management’s explicit statement that capital priorities remain focused on innovation, commercial execution, and returning excess capital when it enhances shareholder value, reflects a disciplined approach to balancing growth with shareholder returns. This is particularly meaningful given Waystar’s improving leverage profile — net leverage declined to 2.7x from 3.0x year-over-year — and its ability to generate $90 million in unlevered free cash flow in Q1 alone, representing a 67% conversion rate of adjusted EBITDA. The company’s investment-grade credit rating upgrades from Moody’s and S&P further reduce financing costs and increase financial flexibility, enabling sustained investment in high-ROI AI initiatives without compromising balance sheet strength. Unlike many peers burdened by high leverage or inconsistent cash generation, Waystar’s combination of recurring revenue (55% of total), high net revenue retention (111%), and expanding platform adoption creates a self-reinforcing cycle where cash flow fuels innovation, which drives retention and expansion, thereby supporting continued buybacks even amid macroeconomic uncertainty. This capital return capability, often overlooked in software peers, acts as a hidden catalyst for valuation multiple expansion as investors recognize the sustainability of free cash flow generation.
Waystar is gaining decisive momentum in the acute care segment, where it has historically underpenetrated relative to ambulatory care, now serving approximately 16 of the top 20 U.S. hospitals and health systems and deriving about 40% of revenue from acute care — a clear sign of successful platform expansion into higher-margin, more complex enterprise accounts. Management highlighted that this progress stems from providers’ growing fatigue with managing over 12 point solutions and their increasing demand for a single, compliant, cyber-secure, end-to-end platform capable of handling eligibility, authorization, claims, denials, appeals, and payments within live workflows. This shift is structural, not temporary, as large health systems consolidate vendors to reduce integration risk and administrative burden, directly favoring Waystar’s unified architecture. The company’s forward-deployed teams working inside real workflows to co-develop AI capabilities ensure that solutions are production-ready and deeply sticky, resulting in long-term contracts with implementation timelines of 6–18 months — a dynamic already reflected in Waystar’s elevated qualified sales pipeline and implementation backlog. This enterprise traction is particularly valuable because acute care clients typically generate higher revenue per customer, exhibit lower churn due to mission-critical dependency, and offer greater cross-sell potential for emerging AI SKUs like prebill anomaly detection and agentic workflows. The acceleration in large, multi-million-dollar bookings — exceeding historical averages and driven by platform sales — validates that Waystar is winning the shift from fragmented point solutions to integrated enterprise platforms, a trend that will compound over time as more providers standardize on a single vendor.

Waystar is positioned to capture significant value from the healthcare revenue cycle labor services market, which represents approximately $100 billion annually, by extending its AI-powered platform beyond the traditional $20 billion software TAM. Management emphasized that embedding Agentic AI into mission-critical workflows allows the company to automate high-volume, repetitive tasks such as denials, prior authorizations, and recoupments, areas where payers are increasingly offsetting previously paid claims with little transparency. This shift is not merely incremental but transformative, as it enables Waystar to monetize outcomes directly tied to labor cost avoidance rather than just software subscriptions. The company’s early traction with its new recruitment solution — reducing reconciliation time by over 80% and enabling one health system to identify $32 million in recoverable revenue — demonstrates a clear path to monetizing this vast addressable market. Furthermore, Waystar’s proprietary data advantage, derived from processing over 7.5 billion transactions annually and clinical insights from one-third of U.S. hospital discharges, creates a formidable moat that competitors cannot easily replicate, especially given the industry’s intolerance for AI hallucinations in regulated environments. This structural shift from selling software to selling autonomous financial outcomes positions Waystar to sustain growth well above its current 10% normalized organic guidance, with AI-driven bookings already constituting 40% of new wins in Q1 and accelerating cross-sell momentum from the Iodine integration, which bridges the critical mid-cycle gap between clinical and financial data.
Waystar’s capital allocation strategy, including the newly authorized $200 million stock repurchase plan, signals strong internal confidence in intrinsic value creation and provides a tangible floor to downside risk while enhancing long-term per-share returns. The repurchase authorization, coupled with management’s explicit statement that capital priorities remain focused on innovation, commercial execution, and returning excess capital when it enhances shareholder value, reflects a disciplined approach to balancing growth with shareholder returns. This is particularly meaningful given Waystar’s improving leverage profile — net leverage declined to 2.7x from 3.0x year-over-year — and its ability to generate $90 million in unlevered free cash flow in Q1 alone, representing a 67% conversion rate of adjusted EBITDA. The company’s investment-grade credit rating upgrades from Moody’s and S&P further reduce financing costs and increase financial flexibility, enabling sustained investment in high-ROI AI initiatives without compromising balance sheet strength. Unlike many peers burdened by high leverage or inconsistent cash generation, Waystar’s combination of recurring revenue (55% of total), high net revenue retention (111%), and expanding platform adoption creates a self-reinforcing cycle where cash flow fuels innovation, which drives retention and expansion, thereby supporting continued buybacks even amid macroeconomic uncertainty. This capital return capability, often overlooked in software peers, acts as a hidden catalyst for valuation multiple expansion as investors recognize the sustainability of free cash flow generation.
Waystar is gaining decisive momentum in the acute care segment, where it has historically underpenetrated relative to ambulatory care, now serving approximately 16 of the top 20 U.S. hospitals and health systems and deriving about 40% of revenue from acute care — a clear sign of successful platform expansion into higher-margin, more complex enterprise accounts. Management highlighted that this progress stems from providers’ growing fatigue with managing over 12 point solutions and their increasing demand for a single, compliant, cyber-secure, end-to-end platform capable of handling eligibility, authorization, claims, denials, appeals, and payments within live workflows. This shift is structural, not temporary, as large health systems consolidate vendors to reduce integration risk and administrative burden, directly favoring Waystar’s unified architecture. The company’s forward-deployed teams working inside real workflows to co-develop AI capabilities ensure that solutions are production-ready and deeply sticky, resulting in long-term contracts with implementation timelines of 6–18 months — a dynamic already reflected in Waystar’s elevated qualified sales pipeline and implementation backlog. This enterprise traction is particularly valuable because acute care clients typically generate higher revenue per customer, exhibit lower churn due to mission-critical dependency, and offer greater cross-sell potential for emerging AI SKUs like prebill anomaly detection and agentic workflows. The acceleration in large, multi-million-dollar bookings — exceeding historical averages and driven by platform sales — validates that Waystar is winning the shift from fragmented point solutions to integrated enterprise platforms, a trend that will compound over time as more providers standardize on a single vendor.

▼ Bear case

Waystar’s patient payment solutions segment, representing approximately 25% of total revenue, faces persistent and underappreciated structural headwinds from the accelerated shift from print to digital patient statements, which management acknowledged reduces top-line revenue on a unit economic basis despite being margin-neutral in cash flow terms. While the company frames this as a positive long-term trend, the reality is that digital statement adoption directly lowers revenue per patient interaction because digital delivery eliminates paper and postage fees that were previously embedded in the revenue model — a fact implicitly confirmed when CFO Steve Oreskovich noted the impact is visible on the top line but neutral at the margin and cash flow level. This dynamic is not merely seasonal; it reflects a permanent behavioral shift in patient engagement driven by provider-led digital transformation initiatives, meaning Waystar will continually face revenue drag in this segment as more clients migrate away from legacy print-based models. Unlike the provider solutions segment, which benefits from higher margins and faster organic growth (13–14% YoY), patient payment solutions are growing at only half that rate, creating a persistent drag on overall revenue growth that could keep organic expansion stubbornly below the low double-digit target even as AI innovation accelerates elsewhere. Furthermore, management’s attempt to isolate weather and utilization impacts as temporary fails to address the fact that this digital conversion is a deliberate, irreversible client-driven strategy — one that Waystar enables but does not control — making it a stealthy, persistent headwall that could undermine investor expectations for reacceleration in the second half of 2026, especially if guidance assumes a return to historical seasonality patterns that no longer apply.
Despite strong AI traction and a compelling vision for an autonomous revenue cycle platform, Waystar remains exposed to significant execution risk in monetizing its new AI-powered SKUs at scale, particularly given the lengthy sales and implementation cycles inherent in enterprise healthcare sales, which can extend from 6 to 18 months for full revenue realization. Management acknowledged that large bookings — including multi-million-dollar platform deals — take considerable time to convert to revenue, and while they highlighted elevated win rates and a record qualified pipeline, they offered no concrete metrics on how quickly new AI capabilities like the recruitment solution or prebill anomaly detection are being adopted across the installed base beyond early adopter anecdotes. The reliance on early adopter programs and hands-on training at events like the Growth Summit suggests that broader market penetration depends heavily on change management, provider readiness to consume AI in workflows, and the ability of Waystar’s go-to-market teams to educate clients — factors that are inherently slower and less predictable than software licensing cycles. This creates a disconnect between the excitement around AI innovation showcased in events like the TIME award announcement and the actual pace of revenue contribution, potentially leading to disappointment if investors expect near-term acceleration from AI SKUs that in reality require prolonged client education, workflow redesign, and organizational buy-in before delivering measurable financial outcomes.
Waystar’s substantial debt load of $1.5 billion in gross debt, while partially offset by strong cash flow generation, presents a material risk to financial flexibility and valuation multiples should macroeconomic conditions deteriorate or interest rates remain elevated for longer than anticipated, a factor management did not adequately stress-test in its forward-looking commentary. Although the company highlighted deleveraging progress — net leverage down to 2.7x from 3.0x — and credit rating upgrades, it did not address how its sensitivity to interest rate changes could impact unlevered free cash flow if rates remain high, especially given that a significant portion of its debt is tied to floating-rate facilities. The $90 million in Q1 unlevered free cash flow, while impressive, leaves limited buffer after interest payments of $20.7 million, meaning any downturn in healthcare transaction volumes — whether from reduced patient utilization, payer pressure on reimbursement rates, or broader economic slowdown — could quickly erode coverage ratios. Furthermore, the company’s reliance on continued healthcare transaction volumes to drive its data network effects makes it vulnerable to consolidation in the provider sector, where fewer, larger health systems could negotiate stricter terms or develop in-house alternatives, reducing Waystar’s addressable market despite its current penetration of ~60% of U.S. patients. Management’s emphasis on long-term TAM expansion through AI labor automation does not sufficiently mitigate the near-term risk that its core transaction-based revenue model could face headwinds from industry consolidation or regulatory shifts that reduce claim volumes, a scenario not meaningfully addressed in the Q&A despite repeated probing on macroeconomic sensitivities.

Waystar’s patient payment solutions segment, representing approximately 25% of total revenue, faces persistent and underappreciated structural headwinds from the accelerated shift from print to digital patient statements, which management acknowledged reduces top-line revenue on a unit economic basis despite being margin-neutral in cash flow terms. While the company frames this as a positive long-term trend, the reality is that digital statement adoption directly lowers revenue per patient interaction because digital delivery eliminates paper and postage fees that were previously embedded in the revenue model — a fact implicitly confirmed when CFO Steve Oreskovich noted the impact is visible on the top line but neutral at the margin and cash flow level. This dynamic is not merely seasonal; it reflects a permanent behavioral shift in patient engagement driven by provider-led digital transformation initiatives, meaning Waystar will continually face revenue drag in this segment as more clients migrate away from legacy print-based models. Unlike the provider solutions segment, which benefits from higher margins and faster organic growth (13–14% YoY), patient payment solutions are growing at only half that rate, creating a persistent drag on overall revenue growth that could keep organic expansion stubbornly below the low double-digit target even as AI innovation accelerates elsewhere. Furthermore, management’s attempt to isolate weather and utilization impacts as temporary fails to address the fact that this digital conversion is a deliberate, irreversible client-driven strategy — one that Waystar enables but does not control — making it a stealthy, persistent headwall that could undermine investor expectations for reacceleration in the second half of 2026, especially if guidance assumes a return to historical seasonality patterns that no longer apply.
Despite strong AI traction and a compelling vision for an autonomous revenue cycle platform, Waystar remains exposed to significant execution risk in monetizing its new AI-powered SKUs at scale, particularly given the lengthy sales and implementation cycles inherent in enterprise healthcare sales, which can extend from 6 to 18 months for full revenue realization. Management acknowledged that large bookings — including multi-million-dollar platform deals — take considerable time to convert to revenue, and while they highlighted elevated win rates and a record qualified pipeline, they offered no concrete metrics on how quickly new AI capabilities like the recruitment solution or prebill anomaly detection are being adopted across the installed base beyond early adopter anecdotes. The reliance on early adopter programs and hands-on training at events like the Growth Summit suggests that broader market penetration depends heavily on change management, provider readiness to consume AI in workflows, and the ability of Waystar’s go-to-market teams to educate clients — factors that are inherently slower and less predictable than software licensing cycles. This creates a disconnect between the excitement around AI innovation showcased in events like the TIME award announcement and the actual pace of revenue contribution, potentially leading to disappointment if investors expect near-term acceleration from AI SKUs that in reality require prolonged client education, workflow redesign, and organizational buy-in before delivering measurable financial outcomes.
Waystar’s substantial debt load of $1.5 billion in gross debt, while partially offset by strong cash flow generation, presents a material risk to financial flexibility and valuation multiples should macroeconomic conditions deteriorate or interest rates remain elevated for longer than anticipated, a factor management did not adequately stress-test in its forward-looking commentary. Although the company highlighted deleveraging progress — net leverage down to 2.7x from 3.0x — and credit rating upgrades, it did not address how its sensitivity to interest rate changes could impact unlevered free cash flow if rates remain high, especially given that a significant portion of its debt is tied to floating-rate facilities. The $90 million in Q1 unlevered free cash flow, while impressive, leaves limited buffer after interest payments of $20.7 million, meaning any downturn in healthcare transaction volumes — whether from reduced patient utilization, payer pressure on reimbursement rates, or broader economic slowdown — could quickly erode coverage ratios. Furthermore, the company’s reliance on continued healthcare transaction volumes to drive its data network effects makes it vulnerable to consolidation in the provider sector, where fewer, larger health systems could negotiate stricter terms or develop in-house alternatives, reducing Waystar’s addressable market despite its current penetration of ~60% of U.S. patients. Management’s emphasis on long-term TAM expansion through AI labor automation does not sufficiently mitigate the near-term risk that its core transaction-based revenue model could face headwinds from industry consolidation or regulatory shifts that reduce claim volumes, a scenario not meaningfully addressed in the Q&A despite repeated probing on macroeconomic sensitivities.

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Health Information Services

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	VEEV	Veeva Systems Inc	29.34 Bn	31.16	8.84	-
2	BTSG	BrightSpring Health Services, Inc.	13.49 Bn	46.18	0.99	2.50 Bn
3	HQY	Healthequity, Inc.	7.96 Bn	34.51	5.95	0.94 Bn
4	TXG	10x Genomics, Inc.	6.17 Bn	-272.14	9.65	-
5	HNGE	Hinge Health, Inc.	6.02 Bn	-11.77	9.31	-
6	MMED	MiniMed Group, Inc.	4.19 Bn	-8.88	1.38	-
7	WAY	Waystar Holding Corp.	4.14 Bn	32.80	3.58	1.47 Bn
8	DOCS	Doximity, Inc.	3.82 Bn	19.51	5.93	-

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password